Creative Planning’s Theriva Biologics TOVX Stock Holding History

Creative Planning’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-40	Closed	-$2K	–	2443
2022 Q2	$2K	Hold	40	–	–	﹤0.01%	2257
2022 Q1	$3K	Hold	40	–	–	﹤0.01%	2288
2021 Q4	$3K	Hold	40	–	–	﹤0.01%	2072
2021 Q3	$5K	Hold	40	–	–	﹤0.01%	2090
2021 Q2	$6K	Sell	40 -5	-11%	-$717	﹤0.01%	2029
2021 Q1	$8K	Buy	+45	New	+$8.89K	﹤0.01%	2493
2018 Q3	–	Sell	-19	Closed	-$40K	–	2171
2018 Q2	$40K	Sell	19 -1	-5%	-$2.3K	﹤0.01%	1868
2018 Q1	$56K	Hold	20	–	–	﹤0.01%	1812
2017 Q4	$89K	Hold	20	–	–	﹤0.01%	1742
2017 Q3	$165K	Hold	20	–	–	﹤0.01%	1647
2017 Q2	$100K	Buy	20 +8	+67%	+$39.8K	﹤0.01%	1996
2017 Q1	$67K	Hold	12	–	–	﹤0.01%	2257
2016 Q4	$82K	Buy	12 +6	+100%	+$61.6K	﹤0.01%	2003
2016 Q3	$95K	Buy	6 +2	+50%	+$29.9K	﹤0.01%	1878
2016 Q2	$59K	Hold	4	–	–	﹤0.01%	2026
2016 Q1	$92K	Hold	4	–	–	﹤0.01%	1686
2015 Q4	$77K	Hold	4	–	–	﹤0.01%	1795
2015 Q3	$84K	Hold	4	–	–	﹤0.01%	1694
2015 Q2	$92K	Buy	+4	New	+$80.3K	﹤0.01%	983
2015 Q1	–	Hold	0	–	–	–	3658
2014 Q4	–	Hold	0	–	-$4K	–	4347
2014 Q3	–	Hold	0	–	–	–	3419
2013 Q4	–	Hold	0	–	-$2K	–	3472
2013 Q3	–	Hold	0	–	–	–	3006

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Creative Planning's TOVX Position: Q3 2022 in Review

Creative Planning sold out of Theriva Biologics (TOVX) in Q3 2022, closing a stake of 40 shares — an estimated $2K sold.

Creative Planning first reported a position in TOVX in Q2 2015 and held it in 19 quarters. The position peaked at $165K in Q3 2017. 24 funds tracked by Wall St. Rank hold TOVX as of Q3 2022.

Creative Planning reported no remaining Theriva Biologics position as of Q3 2022 after selling out during the quarter.
Creative Planning sold 40 Theriva Biologics shares in Q3 2022, an estimated $2K.
Creative Planning first reported a position in Theriva Biologics in Q2 2015 and held it in 19 quarters.
Creative Planning's Theriva Biologics position peaked at $165K in Q3 2017.
24 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2022.

Based on Creative Planning's 13F filing for Q3 2022, filed 3 Nov 2022.